News | July 28, 2022
Novartis India Q1FY23 PAT jumps to Rs. 52.38 Cr
Novartis India has reported total income of Rs. 147.44 crores during the period ended June 30, 2022.
Novartis India has reported total income of Rs. 147.44 crores during the period ended June 30, 2022.
The Velcade Brand and generic had U.S. sales of approximately $1.2 billion MAT for the most recent twelve months ending in May 2022
Dr. Lal Path Labs has reported total income of Rs. 511 crores during the period ended June 30, 2022
Pawar also unveiled the India Family Planning 2030 vision document and launched the Medical Eligibility Criteria (MEC) Wheel Application, E-Module of Family Planning Logistics Management System (FPLMIS) and Digital Archive on Family Planning under the category of Digital Intervention.
Biopharma and CROs to benefit from simplified access to global research sites
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
Aarti Drugs Limited has reported total income of Rs. 622.22 crores during the quarter ended June 30, 2022.
This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines
The company has reported total income of Rs. 186.97 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 94.30 crores during the period ended June 30, 2022.
Subscribe To Our Newsletter & Stay Updated
